Equillium, Inc. (EQ)

Equillium's stock has trended up by 151.23% in the past six months. In November 2025, Equillium reported Q3 earnings that exceeded expectations and announced participation in investor conferences. In October 2025, the company hosted a virtual KOL event to discuss EQ504 and announced leadership and corporate updates. In August 2025, Equillium secured up to $50 million in gross proceeds to advance EQ504 and initially planned to integrate cryptocurrency into its treasury reserve strategy. In April 2025, the FDA declined Breakthrough Therapy designation for itolizumab. In March 2025, Equillium announced positive topline data from its Phase 3 EQUATOR study and a Phase 2 study, and Leerink Partners downgraded Equillium's stock.

There is no readily available information indicating demand seasonality for Equillium, Inc.'s products or services. As a clinical-stage biotechnology company, its revenue streams are primarily derived from licensing agreements and development funding rather than commercial product sales, which typically exhibit seasonality.

Equillium, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for severe autoimmune and inflammatory disorders. The company operates in the Health Care sector, specifically in the Biotechnology: Pharmaceutical Preparations industry. Equillium's core business revolves around advancing its pipeline candidates through clinical trials toward potential regulatory approval and commercialization. Its major product candidates include Itolizumab (EQ001), EQ101, EQ302, and EQ504.

Equillium, Inc. is headquartered in La Jolla, California, United States, with operations extending to Australia and New Zealand.

Equillium's brand reputation is primarily tied to its scientific advancements, clinical trial progress, and commitment to addressing unmet medical needs in severe autoimmune and inflammatory disorders. News regarding clinical trial results, financing rounds, and corporate updates impact investor perception and stock performance. There have been no specific public events in the past year that have broadly affected Equillium's brand reputation in terms of widespread public perception beyond the investment community.

Individual investors are the largest shareholders of Equillium, Inc., holding a 30% ownership stake, while institutions collectively own 25% of the company's shares. Major institutional owners include ADAR1 Capital Management, LLC, Adage Capital Partners Gp, L.l.c., Decheng Capital LLC, Woodline Partners LP, Balyasny Asset Management Llc, StemPoint Capital LP, Takeda Pharmaceutical Co Ltd, Vanguard Group Inc, and Renaissance Technologies Llc. Bruce Steel, the CEO, is also a significant individual shareholder.